万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生3>>生化研究方法
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生2>>药学
您的位置:万维书刊网 >>sci/e期刊大全 >>生物科学>>分析化学

DRUG TESTING AND ANALYSIS《药物检测与分析》 (官网投稿)

简介
  • 期刊简称DRUG TEST ANAL
  • 参考译名《药物检测与分析》
  • 核心类别 SCIE(2023版), 目次收录(知网),外文期刊,
  • IF影响因子
  • 自引率25.40%
  • 主要研究方向医学-BIOCHEMICAL RESEARCH METHODS生化研究方法;CHEMISTRY, ANALYTICAL分析化学;PHARMACOLOGY & PHARMACY药学

主要研究方向:

等待设置主要研究方向
医学-BIOCHEMICAL RESEARCH METHODS生化研究方法;CHEMISTRY, ANALYTICAL分析化学;PHARMACOLOGY & PHARMACY药学

DRUG TESTING AND ANALYSIS《药物检测与分析》(月刊). In addition to the usual publishing fare of primary research articles, case reports and le...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:

https://analyticalsciencejournals.onlinelibrary.wiley.com/journal/19427611

3、投稿网址:https://mc.manuscriptcentral.com/dta

4、官网邮箱:m.thevis@biochem.dshs-koeln.de(主编)

(更多编辑邮箱请查看期刊官网信息)

5、期刊刊期:月刊,一年出版12期。

2021年111日星期

                          

 

投稿须知【官网信息】

 

Author Guidelines

General

Drug Testing and Analysis (DTA) is devoted to the publication of papers dealing with the development and application of techniques for the determination of controlled or controversial substances.

Papers must clearly be of scientific value in the field and will be submitted to two independent referees. Contributions must be in English and must not have been published elsewhere, and authors must agree not to communicate the same material for publication to any other journal. It is in the author's interest to ensure accurate and consistent presentation and thus avoid publication delays. There are no page charges.

The Editors are aware that restrictions may be enforced by certain agencies concerning the provision of comprehensive synthesis methods for controversial substances. Articles without comprehensive synthesis methodologies may be considered at the discretion of the Editor providing the scientific integrity of the article is not compromised. If affected, authors should state explicitly the reason for the omission in their covering letter together with a statement justifying the omission in the submitted article.

Data Protection

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.

Expects Data Sharing

DTA encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.

Visit re3data.org or fairsharing.org to help identify registered and certified data repositories relevant to your subject area.

More information about the Data Sharing Policy can be found here.

Manuscript Submission

All papers must be submitted via the online system. Drug Testing and Analysis operates an online submission and peer review system that allows authors to submit articles online and track their progress via a web interface. Please read the remainder of these instructions to authors and then click http://mc.manuscriptcentral.com/dta to navigate to the Drug Testing and Analysis online submission site.

IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have created an account.

File types. Preferred formats for the text and tables of your manuscript are .docx, .doc, .rtf, .ppt, .xls. LaTeX files may be submitted provided that an .eps or .pdf file is provided in addition to the source files. Figures may be provided in .tiff or .eps format.

INITIAL SUBMISSION

NON-LATEX USERS: Editable source files must be uploaded at this stage. Tables must be on separate pages after the reference list, and not be incorporated into the main text. Figures should be uploaded as separate figure files.

LATEX USERS: For reviewing purposes you should upload a single .pdf that you have generated from your source files. You must use the File Designation "Main Document" from the dropdown box.

REVISION SUBMISSION

NON-LATEX USERS: Editable source files must be uploaded at this stage. Tables must be on separate pages after the reference list, and not be incorporated into the main text. Figures should be uploaded as separate figure files.

LATEX USERS: When submitting your revision you must still upload a single .pdf that you have generated from your now revised source files. You must use the File Designation "Main Document" from the dropdown box. In addition you must upload your TeX source files. For all your source files you must use the File Designation "Supplemental Material not for review". Previous versions of uploaded documents must be deleted. If your manuscript is accepted for publication we will use the files you upload to typeset your article within a totally digital workflow.

Accepted Articles

'Accepted Articles' have been accepted for publication and undergone full peer review but have not been through the copyediting, typesetting, pagination and proofreading process. Accepted Articles are published online a few days after final acceptance, appear in PDF format only (without the accompanying full-text HTML) and are given a Digital Object Identifier (DOI), which allows them to be cited and tracked. The DOI remains unique to a given article in perpetuity. More information about DOIs can be found online at http://www.doi.org/faq.html. Given that Accepted Articles are not considered to be final, please note that changes will be made to an article after Accepted Article online publication, which may lead to differences between this version and the Version of Record.

The Accepted Articles service has been designed to ensure the earliest possible circulation of research papers after acceptance.

Accepted articles will be indexed by PubMed; Therefore the submitting author must carefully check the names and affiliations of all authors provided in the cover page of the manuscript, as it will not be possible to alter these once a paper is made available online in Accepted Article format. Subsequently the final copyedited and proofed articles will appear either as Early View articles in a matter of weeks or in an issue on Wiley Online Library; the link to the article in PubMed will automatically be updated.

……

更多详情:

https://analyticalsciencejournals.onlinelibrary.wiley.com/hub/journal/19427611/homepage/forauthors.html#enged


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭